Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 45.20M | P/E | - | EPS this Y | 10.30% | Ern Qtrly Grth | - |
| Income | -68.27M | Forward P/E | -2.07 | EPS next Y | 42.30% | 50D Avg Chg | -30.00% |
| Sales | 36.92M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -59.00% |
| Dividend | N/A | Price/Book | 1.13 | EPS next 5Y | - | 52W High Chg | -85.00% |
| Recommedations | 2.00 | Quick Ratio | 0.31 | Shares Outstanding | 111.41M | 52W Low Chg | 26.00% |
| Insider Own | 27.01% | ROA | -23.65% | Shares Float | 55.99M | Beta | 1.09 |
| Inst Own | 49.10% | ROE | -182.44% | Shares Shorted/Prior | 3.28M/1.36M | Price | 0.46 |
| Gross Margin | 82.31% | Profit Margin | -184.91% | Avg. Volume | 87,317 | Target Price | 3.20 |
| Oper. Margin | -98.34% | Earnings Date | Nov 8 | Volume | 54,313 | Change | 1.31% |
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Altchem Ltd | 10% Owner 10% Owner | Oct 19 | Sell | 0.04 | 14,122,659 | 564,906 | 4,941,101 | 10/23/23 |
| Altchem Ltd | 10% Owner 10% Owner | Oct 18 | Sell | 0.0646 | 3,421,537 | 221,031 | 19,063,760 | 10/20/23 |
| Schaub James | EVP and COO EVP and COO | Aug 08 | Buy | 1.55 | 150,000 | 232,500 | 540,020 | 08/09/22 |
| MARKISON BRIAN A | Chief Executive Offi.. Chief Executive Officer | Aug 08 | Buy | 1.55 | 850,000 | 1,317,500 | 2,976,020 | 08/09/22 |
| Burgstahler David F | Director Director | Aug 08 | Buy | 1.55 | 8,000,000 | 12,400,000 | 23,730,864 | 08/09/22 |
| Venkataraman Sriram | Director Director | Aug 08 | Buy | 1.55 | 8,000,000 | 12,400,000 | 23,730,864 | 08/09/22 |
| Avista Healthcare Partners, L.... | 10% Owner 10% Owner | Aug 08 | Buy | 1.55 | 8,000,000 | 12,400,000 | 23,730,864 | 08/09/22 |